Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 13/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SDHB | P21912 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945964 | 1.00 | PTPRB (0.49) | PTPRBKDM4ESDHBAPLNRNPC1 | |
| SCHEMBL27921824 | 0.96 | PTPRB (0.49) | PTPRBKDM4ESDHBNPC1SLC6A3 | |
| SCHEMBL3704125 | 0.90 | PTPRB (0.50) | PTPRBKDM4ENPC1SLC6A3 | |
| SCHEMBL3704124 | 0.90 | PTPRB (0.50) | PTPRBKDM4ENPC1SLC6A3 | |
| SCHEMBL3699897 | 0.87 | PTPRB (0.46) | PTPRBKDM4ESDHBAPLNRNPC1 | |
| SCHEMBL3699902 | 0.85 | PTPRB (0.45) | PTPRBKDM4ESDHBNPC1SLC6A3 | |
| SCHEMBL684346 | 0.85 | PTPRB (0.67) | PTPRB | |
| SCHEMBL500965 | 0.85 | PTPRB (0.67) | PTPRB | |
| SCHEMBL20787752 | 0.85 | PTPRB (0.48) | PTPRBKDM4ESDHBNPC1 | |
| SCHEMBL500393 | 0.84 | PTPRB (0.65) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |